My long term goal is to lead an independent research laboratory that translates psychiatric genetics findings into the development of novel therapeutics. My previous training in neuropsychopharmacology brought me to the forefront of contemporary psychiatric drug discovery efforts where I realized that novel therapeutic development is needed. Psychiatric genetics has the potential to uncover novel drug targets and treatment strategies. In order to effectively translate genetic findings to therapeutic drug development, I need the ability to analyze and interpret genetic findings in order to prioritize research and development efforts. My immediate career goal is to obtain the skill set necessary to use genomics data to advance psychotherapeutic development. The proposed 4-year career development award will provide an immersive training opportunity in psychiatric genetics that will enable me to design, execute, analyze, and interpret psychiatric genetic research. The proposed research project investigates the genomics of schizophrenia (SCZ) in a sample of highly treatment resistant subjects. These individuals are actively treated, adherent to prescribed medications, reside in a protected environment, do not abuse drugs, and yet many have been severely psychotic for years. The primary goal is to screen a subject?s genome for rare variation that can cause a clinical presentation initially indistinguishable from SCZ. We hypothesize that highly treatment resistant SCZ subjects have rare genetic mutations of strong effect, such as a Mendelian disease. Analysis of a large and notably severe SCZ sample will provide a rigorous test of this hypothesis. Positive findings could dramatically alter the clinical impact of SCZ genomics due to the availability of effective treatments for some disorders. First, we will establish our sample by obtaining consent, then phenotyping and collecting blood samples of patients. Second, we will perform high-throughput genotyping of these samples using whole exome sequencing and DNA microarrays. Third, we will screen these genomic data for rare variants of strong effect relating to their primary diagnosis and their pharmacological treatment. We will also look for and report any secondary findings. Prior to returning our findings to the medical team, the results will be verified by a CLIA-certified laboratory. Finally, we will identify rare variation for future studies (R01) and analyze the data for variation associated with highly treatment-resistant SCZ. In addition to the scientific and therapeutic benefits inherent in this work, this project provides an immersive training program in human genomics studies that aligns with my career goals. In addition to the training provided by the proposed research, I will also undertake an extensive training plan involving mentorship by leaders in the field of statistical genetics, bioinformatics, and the ethical, legal and social implications of medical genetics. Due to my strong background in neuropsychopharmacology, I will be able to use the skills acquired in the proposed project to launch into an independent research career investigating the therapeutic potential of psychiatric genomics findings. Furthermore, this project will provide a wealth of preliminary data for a subsequent R01 which will be prepared and submitted during year 4 of this training plan.
The goal of this study is to determine whether highly treatment-resistant schizophrenia can be explained by rare genetic variation. There are many rare genetic disorders that have symptoms that mimic schizophrenia, and it is important to identify these disorders because some of them are treatable. This project aims to test whether genetic testing can be used to provide better care for schizophrenia patients. The genetic data obtained will also be used to increase our basic understanding of schizophrenia.